Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
Total Valuation
Springworks Therapeutics has a market cap or net worth of $3.49B. The enterprise value is ―.
Market Cap$3.49B
Enterprise Value―
Share Statistics
Springworks Therapeutics has 75,322,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,322,690
Owned by Insiders2.26%
Owned by Institutions29.81%
Financial Efficiency
Springworks Therapeutics’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -56.88%.
Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-56.88%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee520.62K
Profits Per Employee-701.44K
Employee Count368
Asset Turnover0.33
Inventory Turnover1.23
Valuation Ratios
The current PE Ratio of Springworks Therapeutics is -10.38. Springworks Therapeutics’s PEG ratio is -2.11.
PE Ratio-10.38
PS Ratio0.00
PB Ratio7.31
Price to Fair Value5.57
Price to FCF-19.20
Price to Operating Cash Flow-20.02
PEG Ratio-2.11
Income Statement
In the last 12 months, Springworks Therapeutics had revenue of 191.59M and earned -258.13M in profits. Earnings per share was -3.48.
Revenue191.59M
Gross Profit179.04M
Operating Income-278.13M
Pretax Income-258.13M
Net Income-258.13M
EBITDA-278.13M
Earnings Per Share (EPS)-3.48
Cash Flow
In the last 12 months, operating cash flow was -175.60M and capital expenditures -9.45M, giving a free cash flow of -185.05M billion.
Operating Cash Flow-175.60M
Free Cash Flow-185.05M
Free Cash Flow per Share-2.46
Dividends & Yields
Springworks Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.42
52-Week Price Change9.86%
50-Day Moving Average44.36
200-Day Moving Average40.24
Relative Strength Index (RSI)59.81
Average Volume (3m)7.38M
Important Dates
Springworks Therapeutics upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
Springworks Therapeutics as a current ratio of 3.81, with Debt / Equity ratio of 1.64%
Current Ratio3.81
Quick Ratio3.70
Debt to Market Cap<0.01
Net Debt to EBITDA0.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Springworks Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Springworks Therapeutics EV to EBITDA ratio is -9.41, with an EV/FCF ratio of -14.53.
EV to Sales13.66
EV to EBITDA-9.41
EV to Free Cash Flow-14.53
EV to Operating Cash Flow-14.90
Balance Sheet
Springworks Therapeutics has $307.99M in cash and marketable securities with $7.91M in debt, giving a net cash position of -$300.07M billion.
Cash & Marketable Securities$307.99M
Total Debt$7.91M
Net Cash-$300.07M
Net Cash Per Share-$3.98
Tangible Book Value Per Share$6.28
Margins
Gross margin is 93.07%, with operating margin of -145.17%, and net profit margin of -134.73%.
Gross Margin93.07%
Operating Margin-145.17%
Pretax Margin-134.73%
Net Profit Margin-134.73%
EBITDA Margin-145.17%
EBIT Margin-145.17%
Analyst Forecast
The average price target for Springworks Therapeutics is $55.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$55.57
Price Target Upside19.56% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast730.42%
EPS Growth Forecast31.63%